A binary Xpovio catalyst is set for March.
ApexOnco Front Page
Recent articles
BeOne terminates a MUC1-targeting project.
The company’s latest phase 3 for its biparatopic ADC is in colorectal cancer.
Cogent joins OnKure with a clinical-stage H1047Rm-specific PI3Kα inhibitor.
The company discontinues one of its two KRAS G12D degraders.
A phase 3 trial is downgraded, and the second line now looks like the main focus for turmetabart adizutecan.
After a phase 3 push the livmoniplimab plan falters.
With a slashed valuation the newly listed biotech heads for phase 3.
